XIAFLEX (collagenase clostridium histolyticum) by Auxilius Pharma is conditions, resulting in lysis of collagen deposits. First approved in 2010.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
XIAFLEX is an injectable enzymatic therapy containing collagenase clostridium histolyticum that breaks down collagen deposits in fibrotic conditions. It is approved for Dupuytren's contracture and Peyronie's disease, two conditions characterized by abnormal collagen accumulation in hand cords and penile plaques, respectively. The drug works by enzymatically disrupting Type I and III collagen, reducing contracture severity and penile curvature deformity.
Product is approaching loss of exclusivity with modest Part D spending (~$66M in 2023), suggesting a niche therapeutic with limited team expansion opportunity.
conditions, resulting in lysis of collagen deposits. Injection of XIAFLEX into a Dupuytren’s cord, which is comprised mostly of collagen, may result in enzymatic disruption of the cord. The signs and symptoms of Peyronie’s disease are caused by a collagen plaque. Injection of XIAFLEX into a…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on XIAFLEX at Auxilius Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease
Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex)
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moXIAFLEX offers limited career growth opportunity given its niche indication base, modest commercial revenue (~$66M), and approaching loss of exclusivity. Professionals joining this team should expect a consolidation-phase product focus rather than rapid expansion or innovation-driven roles.